ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs MXN
18.40929
-0.13%
Brent Oil
84.74
0.05%
Bitcoin
66,292.69
2.04%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aileron Therapeutics Inc (ALRN)

  7. Aileron Therapeutics Inc (ALRN) Noticias

ALRN

Aileron Therapeutics (ALRN)

Aileron Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ALRN
FechaHoraFuenteTítuloSímboloCompañía
05/06/202405:58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALRNAileron Therapeutics Inc
16/05/202416:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALRNAileron Therapeutics Inc
15/05/202416:13GlobeNewswire Inc.Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ALRNAileron Therapeutics Inc
15/05/202416:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALRNAileron Therapeutics Inc
06/05/202415:05GlobeNewswire Inc.Aileron Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:ALRNAileron Therapeutics Inc
03/05/202415:05GlobeNewswire Inc.Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionNASDAQ:ALRNAileron Therapeutics Inc
01/05/202407:45GlobeNewswire Inc.Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionNASDAQ:ALRNAileron Therapeutics Inc
01/05/202407:30GlobeNewswire Inc.Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)NASDAQ:ALRNAileron Therapeutics Inc
15/04/202416:20GlobeNewswire Inc.Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:ALRNAileron Therapeutics Inc
12/03/202407:00GlobeNewswire Inc.Aileron Therapeutics Announces CEO TransitionNASDAQ:ALRNAileron Therapeutics Inc
06/03/202416:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALRNAileron Therapeutics Inc
15/02/202415:05GlobeNewswire Inc.Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventNASDAQ:ALRNAileron Therapeutics Inc
05/02/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALRNAileron Therapeutics Inc
05/02/202412:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALRNAileron Therapeutics Inc
01/02/202415:30GlobeNewswire Inc.Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024NASDAQ:ALRNAileron Therapeutics Inc
31/01/202415:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALRNAileron Therapeutics Inc
29/01/202415:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALRNAileron Therapeutics Inc
29/01/202415:10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALRNAileron Therapeutics Inc
29/01/202407:48Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ALRNAileron Therapeutics Inc
29/01/202407:46Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALRNAileron Therapeutics Inc
19/01/202415:44Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALRNAileron Therapeutics Inc
11/01/202415:18Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALRNAileron Therapeutics Inc
16/11/202307:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ALRNAileron Therapeutics Inc
13/11/202316:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALRNAileron Therapeutics Inc
31/10/202311:30PR Newswire (US)Aileron Therapeutics Announces Acquisition of Lung TherapeuticsNASDAQ:ALRNAileron Therapeutics Inc
08/05/202307:01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALRNAileron Therapeutics Inc
28/04/202307:01Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ALRNAileron Therapeutics Inc
23/02/202315:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALRNAileron Therapeutics Inc
21/02/202307:30GlobeNewswire Inc.Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic AlternativesNASDAQ:ALRNAileron Therapeutics Inc
14/02/202310:43Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ALRNAileron Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALRN

Su Consulta Reciente

ASX
OSHKOA
UPBT
DASHETH
Dash
COIN
STWGBP
TG
WELT
Amundi Index Solutions
HITB
BIDRUSDT
BIDR BEP2
BIT
UB51MW
Unicredit Bank
ASX
MPGO
Many Peaks Gold
TG
6LA
Lamar Advertising
USOTC
SWDBF
Swedbank A B (PK)
BITMOT
951219
Btp Tf 3,5% Ge26 Eur
BIT
P1IL09
BNP Paribas Issuance
LSE
62NI
Relx Fin 1.000%
LSE
44WJ
Lloyds Bk.24
AMEX
XMLV
Invesco S&P MidCap Low V...
USOTC
OTGFS
Otis Gallery (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados